Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis

TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Herein, we performed a meta-analysis aimed to evaluate any grade adverse events, grade 3-4 adverse eve...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment and research communications 2023, Vol.37, p.100775-100775, Article 100775
Main Authors: Gadaleta-Caldarola, Gennaro, Lanotte, Laura, Infusino, Stefania, Gadaleta-Caldarola, Arianna, Schipilliti, Francesca Matilde, Citrigno, Claudia, Petrarota, Cataldo, Cusmai, Antonio, Rizzo, Alessandro
Format: Article
Language:English
Subjects:
Antibody drug conjugates
Antineoplastic Agents
Breast cancer
Dato-Dxd
Datopotamab deruxtecan
Humans
Immunoconjugates
Triple Negative Breast Neoplasms - drug therapy
Triple-negative breast cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Herein, we performed a meta-analysis aimed to evaluate any grade adverse events, grade 3-4 adverse events, dose reduction, and serious adverse events in TNBC patients treated with Dato-DXd in clinical trials. The pooled results suggests that Dato-DXd is associated with a favorable safety profile: while any grade treatment-related toxicities were common, grade 3-4 events were not particularly frequent and mainly represented by stomatitis (13.88%; 95% CI, 10.68 - 17.09). These findings may help to comprehensively define the safety profile of Dato-DXd and to assist in the design of future clinical trials in this setting.
ISSN:2468-2942
2468-2942
DOI:10.1016/j.ctarc.2023.100775